Risk Stratification in Renal Cell Carcinoma: A Narrative Review
Cancers · 26.06.2026 · 18 (13) · 2081
DOI: 10.3390/cancers18132081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.06.2026. Verfasst von Nykiera Dixon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) accounts for the majority of kidney cancers, with approximately 80,000 new diagnoses and over 14,000 deaths annually in the United States. Risk stratification is essential for prognostication, treatment selection, and clinical trial design across all disease stages. In localized and locally advanced RCC, pathological stage, histology, and grade remain the primary prognostic factors, while the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria serve as the standard risk stratification tool in the metastatic setting. However, current models rely predominantly on clinical and pathologic variables that act as indirect surrogates of tumor biology and do not account for the molecular heterogeneity inherent to RCC. This narrative review synthesizes and compares established and emerging risk stratification and prognostic models across all stages of RCC. Established models such as the IMDC criteria and the stage, size, grade, and necrosis (SSIGN) score demonstrate robust prognostic performance but are limited by their reliance on clinical and pathologic variables alone. Emerging biomarkers—including circulating tumor DNA, methylated DNA, artificial intelligence-based radiomics, and tissue-based molecular signatures—show promise for improving risk discrimination. The molecular heterogeneity of RCC underscores an urgent need for integrated molecular–clinical–pathologic prognostic tools tailored to specific histologic subtypes to enable more precise, individualized care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Förderung
- National Cancer Institute
Zitieren
APA
Dixon, N., Wong, V., Bicer, F., Dason, S., & Singer, E. A. (2026). Risk Stratification in Renal Cell Carcinoma: A Narrative Review. Cancers, 18(13), 2081. https://doi.org/10.3390/cancers18132081
Vancouver
Dixon N, Wong V, Bicer F, Dason S, Singer EA. Risk Stratification in Renal Cell Carcinoma: A Narrative Review. Cancers. 2026;18(13):2081. doi:10.3390/cancers18132081
BibTeX
@article{Dixon2026,
author = {Dixon, Nykiera and Wong, Vivian and Bicer, Fuat and Dason, Shawn and Singer, Eric A},
title = {Risk Stratification in Renal Cell Carcinoma: A Narrative Review},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2081},
doi = {10.3390/cancers18132081}
}
EUVIMED